Medivation

Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Endpoints
Tue, 10/4/22 - 11:06 am
Pfizer
Xtandi
Talzenna
PARP inhibitors
Medivation
clinical trials
prostate cancer
5 years after Pfizer buyout, SEC charges Medivation's ex-dealmaking lead with insider trading
Fierce Pharma
Tue, 08/17/21 - 10:49 pm
Medivation
Pfizer
M&A
SEC
insider trading
Can This Pharma's $14 Billion Bet Succeed?
Motley Fool
Tue, 06/12/18 - 09:39 am
Pfizer
M&A
Medivation
Xtandi
talazoparib
The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug
Stat
Thu, 09/7/17 - 09:35 am
Alzheimer's disease
Axovant
David Hung
dimebon
Medivation
intepirdine
The top 15 highest-paid biopharma executives
Fierce Pharma
Fri, 07/14/17 - 08:42 am
executive pay
Mylan Labs
Valeant Pharmaceuticals
Medivation
Regeneron
JNJ
Merck
Pfizer's $14B Medivation deal's now a cautionary M&A tale, thanks to ASCO: analyst
Fierce Pharma
Tue, 06/6/17 - 09:41 am
Pfizer
Medivation
M&A
ASCO 2017
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
Fierce Pharma
Wed, 05/3/17 - 02:15 pm
Pfizer
Xtandi
Medivation
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
Fierce Pharma
Mon, 04/10/17 - 10:19 am
M&A
Stada
Shire
Baxalta
JNJ
Actelion
Mylan Labs
Pfizer
Takeda
Ariad Pharmaceuticals
Medivation
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Endpoints
Wed, 02/22/17 - 11:43 am
M&A
Shire
Baxalta
Pfizer
Medivation
Mylan
Meda
AbbVie
Stemcentrx
Anacor
The Best Biopharma CEOs of 2016 Are...
TheStreet.com
Mon, 12/19/16 - 11:56 am
Pharma CEOs
Ken Frazier
Merck
David Hung
Medivation
Scott Jackson
Celator Pharmaceuticals
Ed Kaye
Sarepta Therapeutics
Mike Morrissey
Exelixis
What Happened in Biotech in 2016?
Motley Fool
Tue, 11/22/16 - 09:57 pm
biotech
M&A
biosimilars
IPOs
Editas Medicine
CRISPR Therapeutics
Pfizer
Medivation
Celgene
Juno Therapeutics
Sarepta Therapeutics
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Tue, 10/4/16 - 10:07 am
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
A Look at the Pfizer-Medivation Deal
Market Realist
Sun, 10/2/16 - 10:17 am
Pfizer
Medivation
M&A
Pfizer Completes Acquisition of Medivation
Yahoo
Wed, 09/28/16 - 10:16 am
Pfizer
Medivation
M&A
Is This Pfizer's Next Mega-Blockbuster Cancer Drug?
Motley Fool
Tue, 09/27/16 - 10:51 am
Pfizer
Medivation
Xtandi
avelumab
Merck KGaA
Ibrance
Pfizer: Hospira Is Future; Xtandi Is Today's Meal
Yahoo/GuruFocus
Mon, 09/19/16 - 06:04 pm
Pfizer
Hospira
Xtandi
M&A
Medivation
After Losing Medivation, Who Is Gilead Going After Next?
Forbes
Mon, 09/19/16 - 03:39 pm
Medivation
Gilead Sciences
M&A
Puma Biotechnology
Kite Pharma
Incyte
Portola Pharmaceuticals
Key FDA Decisions and Trial Results Coming in the Next 2 Months
24/7 Wall St
Wed, 09/14/16 - 11:53 pm
FDA
clinical trials
Array Biopharma
binimetinib
Mast Therapeutics
Novavax
RSV F vaccine
Threshold Pharmaceuticals
tarloxotinib
Cerulean Pharma
Vertex Pharmaceuticals
Orkambi
Exelixis
cabozantinib
Cobimetinib
Medivation
Xtandi
Celldex
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Thu, 09/8/16 - 09:50 am
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
How did Pfizer swat off rival Medivation bidders? Price, yes, but a CEO confab helped
Fierce Pharma
Fri, 09/2/16 - 11:23 am
Pfizer
Medivation
M&A
Pharma CEOs

Pages